Plant ID: NPO12465
Plant Latin Name: Glycyrrhiza yunnanensis
Taxonomy Genus: Glycyrrhiza
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
912971
Plant-of-the-World-Online:
n.a.
China
MAPK1; | |
HSD17B10; HPGD; ALDH1A1; AKR1B1; | |
KDM4E; | |
NFKB1; | |
THPO; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.587E-12 | 5.317E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.517E-11 | 4.636E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.075E-10 | 4.683E-07 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.212E-09 | 3.770E-06 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.907E-09 | 1.913E-05 | CYP19A1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 2.178E-08 | 3.068E-05 | AKR1B1, ALDH1A1, CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4, HPGD, HSD17B10, MAPK1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 3.068E-05 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.626E-08 | 4.156E-05 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.642E-08 | 6.833E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.904E-08 | 6.833E-05 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.000E-07 | 3.629E-04 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.322E-07 | 4.635E-04 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.803E-07 | 5.859E-04 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.101E-06 | 7.262E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.022E-05 | 6.016E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 1.064E-05 | 6.098E-03 | AKR1B1, CYP19A1, CYP3A4 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.532E-09 | 4.521E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 9.923E-08 | 5.398E-06 | CYP2C9, CYP1A2, ALDH1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.265E-07 | 5.398E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.552E-07 | 1.165E-05 | CYP2C9, CYP1A2, ALDH1A1, AKR1B1, CYP2C19, CYP3A4, CYP19A1, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.546E-07 | 8.148E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.236E-06 | 1.757E-04 | CYP1A2, CYP3A4, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.650E-05 | 3.017E-04 | CYP2C9, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.949E-05 | 9.519E-04 | CYP2C9, MAPK1, CYP2C19 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.155E-04 | 1.642E-03 | LMNA, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.104E-04 | 8.262E-03 | MAPK1, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.400E-04 | 8.262E-03 | CYP2C9, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 9.514E-04 | 8.262E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 7.104E-04 | 8.262E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.131E-03 | 8.262E-03 | MAPK1, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.162E-03 | 8.262E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.162E-03 | 8.262E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.162E-03 | 8.262E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 9.229E-04 | 8.262E-03 | MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.226E-03 | 8.262E-03 | MAPK1, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |